Alfa Cytology, a research solutions provider, focused on cancer therapeutic development and preclinical studies. From the complex phases of target discovery to IND application, we offer a seamless experience. Alfa Cytology specializes in providing comprehensive and efficient preclinical research services to meet the diverse needs of drug development. Our services include drug efficacy studies, pharmacokinetic studies, drug safety evaluations, etc.
Learn More
Learn about our research services dedicated to understanding and treating eye cancers, with a focus...
Discover our comprehensive range of services for gynecologic cancer research, offering advanced...
Learn about our cutting-edge solutions for studying and combating head and neck cancers, providing...
Explore our research services focused on understanding and addressing lung cancers...
Discover our expertise in skin cancer research, offering advanced diagnostic tools, molecular...
Learn how our comprehensive range of services can support bladder cancer research, providing valuable...
Discover our specialized services tailored to studying cancers of the lymphatic system and blood...
Learn about our cutting-edge solutions for studying and combating bone and soft tissue cancers...
Explore our services focused on understanding and addressing brain and nervous system cancers...
Learn how our comprehensive range of services can support breast cancer research, from biomarker discovery...
Discover our expertise in gastrointestinal cancer research, providing valuable insights into...
Explore our specialized services for studying thyroid cancer, including hormone-based therapies...
Alfa Cytology, based in New York, USA, is a research solutions provider, focused on cancer therapeutic development and preclinical studies.
Scientific Excellence
Customized Solutions
Collaborative Approach
Data
Security
PrimePDX™ combines a PBMC-humanized immune baseline with single-cell/small-aggregate initiation and early-passage use, plus optional human CAF microenvironment. The result is an integrated in vitro-to-in vivo workflow that accelerates confident decisions on candidate selection, combinations, and immune mechanisms.
Hu-Immune™ is humanized immune system research engine for immunotherapy R&D. We reconstruct the human immune system in immunodeficient mice and provide an integrated offering that spans model supply and in vivo preclinical efficacy assessment. We offer two model routes—huPBMC humanized model and huHSC humanized model—to meet both rapid, strong immune readouts and multi-lineage, long-term, system-level research needs.
We specialize in developing therapies that target immune checkpoints, such as PD-1, PD-L1, and CTLA-4, to enhance the body's immune response to cancer cells.
Learn More
Our services focus on the development of growth inhibitors to disrupt cancer cell growth pathways, e.g., CDK, VEGF-VEGFR, PI3K/AKT/mTOR pathway, PARP, and disrupt tumor cell survival.
Learn More
Our company is dedicated to the development of cytokine and chemokine pathway inhibitors that inhibit angiogenesis and interfere with tumor cell metabolism, e.g., inhibition of TNF-α, IL-1, IL-6, chemokine receptors, etc.
Learn More
We offer expertise in developing inhibitors that target specific protein kinases implicated in cancer, e.g., EGFR, HER2, ALK .
Learn More
Our company focuses on the development of tumor stem cell inhibitors, with a particular focus on key signaling pathway inhibitors such as Notch and Wnt.
Learn More
Our company is deeply engaged in the research field of TAM modulator, especially in the three key targets of AXL, MER and TYRO3.
Learn More
In our company's scientific research, the study of NK modulators has been at the core of our research, especially on a series of key targets such as NKG2D, NKp30, NKp44, NKp46, NKG2A, and KIR.
Learn More
IAP Inhibitors research has always been at the core of our company's research, and we have focused on the in-depth study of key targets such as XIAP, cIAP1, and the NF-κB pathway.
Learn More
In the field of autophagy modulator research, our company has a deep professional background and unique technical advantages, with a special focus on key targets such as VPS34, ATG, mTOR and Beclin 1.
Learn More
Our services encompass target identification, lead optimization, medicinal chemistry, and preclinical evaluation of small molecule drugs.
Our services include antibody discovery, engineering, optimization, and production, with the aim of developing targeted and immunotherapeutic approaches to cancer treatment.
Our expertise lies in the development and optimization of cell therapies, contributing to the advancement of personalized and immunotherapeutic strategies against cancer.
Our services cover gene delivery systems, gene editing technologies, and the development of viral vectors to enable precise and targeted interventions in cancer cells.
Our services encompass antigen selection, vaccine design, and immunogenicity evaluation, contributing to the development of preventive and therapeutic cancer vaccines.
Our expertise includes peptide design, synthesis, modification, and pharmacological evaluation, enabling the development of tailored and targeted peptide therapeutics.
Alfa Cytology offers foundational insights into cancer's biological processes and mechanisms.
These services focus on developing advanced cancer diagnostic tools and technologies.
Cancer Modeling ServicesUtilizing in vivo and in vitro models to understand cancer progression.
Alfa Cytology provides advanced cancer drug development services for oncology research and innovation.
Alfa Cytology is a leading provider of comprehensive preclinical research services, offering innovative solutions to support medical breakthroughs.
As a committed preclinical research service provider focused on cancer, Alfa Ctytology’s one-stop drug discovery services and a range of technology platforms will address the diverse needs of our clients, guaranteeing innovative and effective research results.
Learn MoreAs a committed preclinical research service provider focused on cancer, Alfa Ctytology’s one-stop drug discovery services and a range of technology platforms will address the diverse needs of our clients, guaranteeing innovative and effective research results.
Learn MoreAlfa Cytology offers Single B Cell Technology, a cutting-edge platform for the discovery of antibodies, enabling the identification and development of highly specific and effective therapeutic antibodies.
Learn MoreAlfa Cytology offers a cutting-edge High-Throughput Screening (HTS) platform to accelerate the discovery and development of new drugs for pancreatic cancer treatment, enabling researchers to efficiently identify promising therapeutic candidates.
Learn MoreAlfa Cytology specializes in the development of innovative antibody-drug conjugates (ADCs) for breast cancer therapies, leveraging the specificity of monoclonal antibodies and the potency of cytotoxic drugs.
Learn MorePARP inhibitors are a groundbreaking cancer therapy significantly improved by PDX models, which reliably replicate tumor characteristics and drug responses, with Alfa Cytology specializing in custom PDX models for PARP inhibitor development.
Learn More
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.
Copyright © 2025 Alfa Cytology. All rights reserved.
